Sponsors
The bill preserves and expands SBIR/STTR commercialization supports and access to later-stage awards through FY2030—benefiting many small businesses and researchers—but increases the risk that funding concentrates among established performers, may bypass early-stage entrants, and requires continued taxpayer and administrative commitments.
Small businesses, startups, and researchers keep access to SBIR/STTR funding and related supports through FY2030, avoiding program disruption and preserving federal R&D and contracting opportunities that help move research toward commercialization and jobs.
Small businesses and awardees can pursue larger follow-on awards more quickly because more agencies are authorized to use direct-to-Phase-II awards (with NIH allowed up to a 15% share), improving access to later-stage SBIR/STTR funding and accelerating commercialization.
Early-stage entrepreneurs and researchers gain extended access to Phase 0 proof-of-concept partnerships and commercialization assistance pilots for up to five additional years, increasing opportunities for proof-of-concept support, tech transfer, and market readiness.
Small, first-time, and diverse applicants risk reduced access because expanding direct-to-Phase-II authority (and lack of detailed guardrails) can concentrate SBIR/STTR funding in fewer, established performers and allow funds to bypass Phase I, shrinking opportunities for newcomers.
Taxpayers face continued and possibly higher federal spending and administrative costs because extending program authorities and pilot programs through FY2030 requires ongoing budgetary commitments and SBA resources instead of allowing expiration.
Recipients and program managers face planning uncertainty because repeated short-term extensions of pilot authority delay comprehensive evaluation or permanent authorization, complicating long-term strategy and investment decisions.
Based on analysis of 4 sections of legislative text.
Extends and broadens SBIR/STTR direct-to-Phase-II and pilot program authorities through 2030, adds per-agency caps (10%/15% for NIH), and requires reporting of awards.
Introduced June 9, 2025 by Johnny Olszewski · Last progress June 9, 2025
Extends and expands several SBIR/STTR authorities and pilot programs through 2030, allowing more federal agencies to use a "direct to Phase II" award pathway, adding per-agency caps on such awards (10% generally, 15% for NIH), and requiring agencies that use the authority to report award counts and amounts. Also extends existing pilot programs (Phase 0 proof-of-concept and commercialization assistance) through September 30, 2030 and updates terminology in one program provision.